Patents

US 12090225 B2: Specially formulated compositions of inhaled nintedanib and nintedanib salts

Granted
2024-09-17
Filed
2021-09-08 application 17469594
Type
Utility · 23 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Disclosed herein are formulations of nintedanib and salts thereof, indolinone derivative compounds and salts thereof for aerosolization and use of such formulations for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. Formulations and delivery options described herein allow for efficacious local delivery of nintedanib or a indolinone derivative compound or salt thereof. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that benefit by reformulation and inhalation administration.

Source: PVGPATDIS, file of 2026-04-10 (ipg240917.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
AVALYN PHARMA INC. 13 patentsUS company or organizationCambridge, MAAvalyn Pharma Inc. State business registration EXACT high confidence: identical full name and state
Avalyn Pharma Inc. Form D issuer EXACT high confidence: identical full name and state
AVALYN PHARMA INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Mark William SurberSan Diego, CA31PVGPATDIS, file of 2026-04-10
Stephen PhamSan Diego, CA17PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K9/0078PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2021-09-08Assignment
Assignment of assignor's interest
PHAM, STEPHEN signed 2018-09-20
SURBER, MARK WILLIAM signed 2018-09-20
AVALYN PHARMA INC. SEATTLE, WA57416/573ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.